InMed Pharmaceuticals Inc. 8-K

What Happened
InMed Pharmaceuticals (INM) announced its financial results for the third quarter of fiscal 2026 (quarter ended March 31, 2026). The company issued a news release on May 6, 2026 and furnished that release to the SEC in an 8‑K filed on May 7, 2026 under Item 7.01 (Regulation FD Disclosure).

Key Details

• Reporting event: Q3 FY2026 financial results for the quarter ended March 31, 2026.
• Announcement timing: News release dated May 6, 2026; Form 8‑K filed May 7, 2026.
• Exhibit furnished: Press release is included as Exhibit 99.1 to the 8‑K (furnished, not filed).
• Filing also includes the company’s interactive cover page data in the submitted inline XBRL file.

Why It Matters
Earnings and quarterly financial disclosures are primary drivers of short‑term stock moves and provide investors with updated visibility into company performance. This 8‑K signals that InMed has publicly released its latest quarterly results; investors should review the May 6 press release (Exhibit 99.1) and any associated financial statements or presentations for revenue, profit/loss, cash position and guidance details to assess near‑term outlook.